Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways
BioCentury's Grand Rounds Europe conference in Amsterdam gathered biotech leaders to discuss emerging therapeutic mechanisms, the role of fundamental biology in drug discovery, and the importance of entrepreneurship in European biotech. Key themes included the potential of GLP-1 successors, aging biology, the risks of over-complex molecular constructs, and the need for hypothesis-driven science over permutation testing.
Summary
This special edition of the BioCentury This Week podcast was recorded live from Grand Rounds Europe 2024 in Amsterdam, featuring panel discussions and fireside chats with EMA Executive Director Emer Cook and GenXus CEO Karen Massey. The conference brought together approximately 300-400 biotech professionals, academics, and investors for networking and knowledge exchange.
A central discussion focused on the academia-industry interface in Europe. While the conference successfully attracted academics and entrepreneurs, panelists noted that many European academics lack exposure to entrepreneurship and business acumen compared to their American counterparts. Dinko Valero emphasized that European entrepreneurship is not culturally ingrained as it is in the US, but highlighted that the landscape is shifting with new funding mechanisms from InvestNL and the European Commission. Importantly, Valero stressed that the primary bottleneck in Europe is not funding or science quality, but rather lack of entrepreneurial thinking and the tendency for successful biotech founders to seek capital from US investors even for European companies.
On emerging science and therapeutic mechanisms, Selena Koch identified several cross-cutting themes: the search for the next foundational mechanism after GLP-1, aging biology as a unifying framework, and specific areas like women's health as a lens for understanding regeneration (particularly endometrial remodeling and ovarian aging). Luke O'Neill's keynote on mitochondria as an "enemy within" sparked discussion about how loss of mitochondrial cloaking and exposure to cellular defenses relates to aging. Sleep and inflammation (particularly NETs) emerged as cross-cutting lenses for understanding multiple disease indications.
A significant portion of discussion addressed the trend toward increasingly complex multi-specific molecular constructs. Oscar Slotboom flagged concerns about "Frankenstein molecules" with six or seven different specificities, noting that enthusiasm for applying all available tools has sometimes overshadowed biology-driven thinking. Multiple panelists agreed that the pendulum has swung too far toward permutation-based discovery, returning to high-throughput screening principles rather than hypothesis-driven science. Even with AI and autonomous labs, speakers emphasized the need to retain hypothesis-driven approaches and incorporate domain knowledge.
The autonomous labs panel revealed that successful automation requires three integrated levels of operation, with a critical insight that knowledge—both the practical troubleshooting knowledge of technicians and the biological knowledge for model-driven decision making—must be embedded in the system. Without this knowledge integration, capital and operating costs become prohibitive.
Finally, the Lp(a) clinical trial failure received substantial attention as a landmark result rippling through the industry. Panelists debated whether poor results indicated misunderstood biology, patient selection errors, or fundamental questions about genetic targets as the sole validation approach. John Kosterlein suggested patient selection played a significant role, while others attributed it to biology. The broader point was that genetic validation, while increasingly demanded by investors, is not a guarantee of success and requires deeper understanding of how that data was generated.
About this episode
Mechanisms broad enough to matter across many diseases, from mitochondrial health to the biology of aging, emerged as a defining theme at Grand Rounds Europe in Amsterdam. On a special live edition of the BioCentury This Week podcast, BioGeneration Ventures' Oskar Slotboom, NautaDutilh's Ruud Smits and Leyden Labs' Dinko Valerio join BioCentury's analysts to discuss women's health and sleep as lenses on disease, and the shift toward prevention. The panel also weighs the limits of "Frankenstei...
Key Insights
- European entrepreneurs do not view entrepreneurship as culturally ingrained compared to Americans, and many academics focus solely on experimental work rather than understanding how to engage with investors and advance commercialization.
- The primary bottleneck for European biotech is not money or scientific talent, but rather the lack of entrepreneurial thinking and the common pattern of European companies raising capital exclusively from US investors rather than local sources.
- European funding mechanisms from InvestNL and the European Commission are becoming more aggressive and serious, though still slower-paced than desired, opening opportunities that were previously geopolitically constrained.
- Dinko Valero emphasized the critical importance of surrounding oneself with top-tier people early and understanding that accepting money from investors creates binding long-term relationships that cannot be unilaterally dissolved.
- The endometrial system's remarkable ability to undergo monthly remodeling despite massive blood loss without scarring could serve as a model for understanding regeneration and tissue remodeling more broadly in the body.
- The ovary ages rapidly compared to other organs, and understanding ovarian health span extension could provide insights applicable to understanding aging mechanisms systemically across other tissues.
- The field has swung too far toward applying all available molecular tools and creating multi-paratopic constructs without adequate hypothesis-driven reasoning, essentially reverting to high-throughput screening with different technology.
- Autonomous labs require embedded knowledge at multiple levels—practical troubleshooting knowledge from technicians and biological decision-making knowledge for models to interpret data—or they cannot achieve true autonomy and will require expensive human oversight.
Topics
Transcript
Welcome to a special edition of the BioCentury This Week podcast. I'm Steven Hansen, Director of BioPharm Intelligence here at BioCentury, and we are coming to you from beautiful Amsterdam in the Netherlands, where we are wrapping up the second annual edition of our Grand Rounds Europe conference. Joining me to discuss key takeaways from the event are Oskar Slotboom, Managing Partner at BioGeneration Ventures, Ruth Smits, Partner at Now32. Thank you very much, appreciate that, I wasn't even going to try myself on that one. Dinko Valero, Co-Founder and Chairman of Leyden Labs. And then from the BioSentry side we have our Executive Editor and head of intelligence research, Selina Koch. Last, but certainly by no means least, our…
Full transcript available for MurmurCast members
Sign Up to AccessMore from BioCentury This Week
Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs
Episode 388 covers three major biotech topics: Electra's biotech IPO upsized but fell 12% on its first trading day, marking an end to a winning streak; fatal toxicities in Novartis' autoimmune CAR-T trial raise safety concerns across the sector; and pharma tariffs set for September 29th lack clear implementation guidance, disproportionately affecting small and mid-sized companies.
Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs
Novartis experienced three major clinical trial failures in one week, wiping out $40 billion in market cap, with the most significant being the failed Phase 3 for Pellicarson (anti-LP(a) antisense therapy). The episode discusses potential explanations for the failure and broader implications for RNA therapeutics and cardiovascular drug development, while also covering pharma M&A trends showing increased focus on disruptive technologies and rising China biotech partnerships.
Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs
Novartis suffered three major clinical trial failures in one week, losing $40 billion in market cap, particularly from the failed LP(a)-targeting antisense therapy Pelacarsen, raising questions about the molecule, target, and timing of intervention. Pharma companies are increasingly embracing disruptive technologies like bispecifics, in vivo CAR-Ts, and siRNAs through licensing deals and M&A, with Eli Lilly leading dealmaking activity; meanwhile, the Trump administration is pressuring mid-tier U.S. biotechs to sign Most Favored Nation drug pricing agreements with unclear terms.
Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton
This BioCentury podcast episode covers three major healthcare policy developments: the Trump administration's Most Favored Nation (MFN) drug pricing deals with 17 pharmaceutical companies, Eli Lilly's $2.9 billion acquisition of Merida for autoimmune disease therapeutics, and the nomination of Heidi Overton as FDA commissioner, alongside RevMed's rapid FDA approval for a pancreatic cancer therapy.
Ep. 384 - Back to School Special: The global FIH trials race
This special BioCentury podcast episode examines global reforms to accelerate first-in-human (FIH) clinical trials, analyzing how China's speed has prompted regulatory changes across the US, Australia, Europe, and Asia. The discussion reveals that success depends less on geopolitics and more on rethinking risk management paradigms, with 73% convergence on specific reforms across major proposals, though implementation varies significantly by jurisdiction.